Potential impact of urolithin A on pathways relevant to sleep health: a mini review
Ana Clara da C. Pinaffi-Langley 1
Faris M. Zuraikat 2,3
Marie-Pierre St-Onge 2
Andriy Yabluchanskiy 1*
1. Department of Neurosurgery, College of Medicine, University of Oklahoma Health Campus, Oklahoma City, OK, United States
2. Division of General Medicine and Center of Excellence for Sleep & Circadian Research, Department of Medicine, Columbia University Irving Medical Center, New York, NY, United States
3. Institute of Human Nutrition, Vagelos College of Physicians & Surgeons, Columbia University Irving Medical Center, New York, NY, United States
Article metrics
View details
Abstract
Sleep is vital to human health, and poor sleep health has been associated with numerous chronic conditions, including cardiovascular disease, obesity, depression, and type 2 diabetes. Recently, an emerging area of research has focused on the relationship between dietary polyphenols and sleep health. This connection may be mediated by the gut microbiota and polyphenol-derived microbial metabolites, which also exert biologically relevant effects. One such metabolite, urolithin A, has been shown to improve mitochondrial function, muscle strength, and inflammation in humans. However, its potential effect on sleep remains unexplored. Thus, this mini review aimed to summarize the current evidence on the effect of urolithin A on sleep-relevant pathways and to explore the possible mechanisms underlying this effect. Although no study directly investigating the effect of urolithin A on sleep outcomes was identified, our search found four preclinical studies that included outcomes relevant to sleep. These studies provide mechanistic plausibility for the relationship between urolithin A and sleep health through direct and indirect mechanisms such as modulation of the central clock, protection against neuroinflammation caused by sleep deprivation, and modulation of the gut microbiota. However, to elucidate the direct effect of urolithin A on sleep, studies with specific sleep measures such as electroencephalogram, actigraphy, and/or polysomnography are still required. Taken together, this represents a novel direction in polyphenol-derived microbial metabolite research with many opportunities for future research.
1 Introduction
Healthful sleep-encompassing its multiple dimensions of regularity, satisfaction, duration, continuity, timing, architecture, (absence of) disorders, and daytime functioning-is vital to human health (1, 2). Several meta-analyses have reported associations between poor sleep health, especially short sleep duration, and an increased risk of type 2 diabetes mellitus (3, 4), cardiovascular disease (5, 6), cognitive impairment and dementia (7–9), and all-cause mortality (10). Despite this strong evidence, poor sleep health is widespread across age ranges and populations. Data from nationally representative surveys show that almost 1 in 3 US adults report sleep disturbances or sleep deprivation (11), while almost 1 in 2 report poor sleep satisfaction (12). These statistics underscore the need to develop novel, actionable strategies to help individuals achieve regular, restorative sleep.
Many factors influence sleep health, including social (e.g., socioeconomic status and work obligations), and individual factors (e.g., lifestyle choices). Lifestyle determinants of sleep are more readily amenable to modification. For example, dietary habits-such as adhering to a healthful diet rich in vegetables, fruits, legumes, unsaturated fats, and whole grains-are strongly correlated with sleep health (13–15). Healthful dietary patterns shown to predict sleep outcomes tend to be rich in polyphenols, secondary plant metabolites with biological effects relevant to human health (16). Thus, an emerging research avenue garnering interest is the effect of polyphenols on sleep health (17–19). While studies have focused on associations of polyphenol intake with sleep outcomes, it is notable that this connection may be mediated by the gut microbiota. As polyphenols are poorly bioavailable, they accumulate in the colon and are extensively metabolized by the resident gut bacteria, generating polyphenol-derived microbial metabolites. These metabolites exert biologically relevant effects of their own and have greater bioavailability than their parent polyphenolic compounds (20), representing a likely mediator of polyphenol’s effect on health outcomes, including on sleep health. One such metabolite, urolithin A, has been shown to improve mitochondrial function and inflammation in humans (21–24). The potential effect of urolithin A on sleep, however, is largely unexplored. Therefore, this mini review aims to summarize the current evidence surrounding the effect of urolithin A on biological pathways relevant to sleep health and explore possible mechanisms by which this polyphenolic metabolite could impact sleep, thereby highlighting future opportunities for research.
2 Urolithin A: brief overview
Urolithin A is an organic compound belonging to the benzo-coumarin class and a member of the broader family of urolithins. Urolithins are microbial metabolites derived from ellagitannins and ellagic acid, polyphenols naturally present in foods such as berries, pomegranate, and nuts (25). These parent polyphenols exhibit low bioavailability and accumulate in the colon, where they are catabolized by specific gut bacterial species to generate urolithins, including urolithin A. Although the identities of the bacteria involved in urolithin biosynthesis are only partially known, members of the Gordonibacter and Ellagibacter genera have been implicated in this process (25, 26).
The biosynthesis of urolithin A comprises several catabolic reactions happening mainly in the colon. The first step involves ester hydrolysis to release ellagic acid moieties from their associated sugars. Once released, ellagic acid undergoes cleavage of a carbon–oxygen bond, resulting in lactone ring opening, followed by a decarboxylation reaction that yields the first urolithin intermediate. Subsequent de-hydroxylation reactions generate urolithins with varying degrees of hydroxylation, with urolithin A being a dihydroxy urolithin (20, 27).
Following their production in the colon, urolithins are absorbed and transported to the liver, where they undergo phase II biotransformation prior to entering the systemic circulation. One of these phase II metabolites, urolithin A-glucuronide, represents urolithin A’s predominant circulating metabolite. In healthy adults, plasma concentrations of urolithin A-glucuronide reach a peak of approximately 110 ng/mL and 30 ng/mL at 24 h post consumption of pomegranate juice (107 mg of ellagitannins and ellagic acid) (28) and frozen red raspberry beverage (29 mg of ellagitannins and ellagic acid) (29), respectively. The pharmacokinetics of urolithin A also vary considerably depending on whether the intake was food-based (i.e., foods rich in ellagitannins) or supplement-based (i.e., isolated urolithin A). Plasma urolithin A and its phase-II conjugates reach peak concentration about 6 h post-intake when supplemented directly, whereas peak concentration happens about 24 h post-intake when given via food (21, 25, 28).
Individuals are commonly classified as urolithin A producers (metabotype A), urolithin A, B, and isourolithin A producers (metabotype B), or non-producers (metabotype 0), according to their urolithin production following an acute dose of ellagitannins and/or ellagic acid (25). However, this classification is not static and can change over time due to factors such as age and dietary habits. In fact, studies using foods rich in ellagitannins have reported metabotype conversion from baseline to endpoint (30). Interindividual variability is high even when circumventing the gut microbiota with isolated metabolites, with plasma urolithin A-glucuronide levels in healthy adults exhibiting a 49% relative coefficient of variation after a standardized dose of 500 mg of urolithin A (28). This is likely due to interindividual differences in absorption, entero-hepatobiliary circulation, and other factors associated with bioavailability. Among adults aged 20–72 years, the metabotype distribution has been reported to be approximately 50–55% metabotype A, 35–40% metabotype B, and 7–10% metabotype 0 (31, 32). Importantly, these studies were conducted in the Mediterranean region (Spain) and, given that genetic and environmental factors both influence metabotype, it is unknown whether these reported metabotype distributions are generalizable to other populations.
3 Urolithin A and sleep: current evidence
For this mini-review, we utilized a hypothesis-based scoping review method where we conducted a search on PubMed, Scopus and Ovid utilizing the terms “urolithin A” and “sleep,” “urolithin A” and “circadian,” and “urolithin A” and “serotonin or tryptophan.” Our inclusion criteria were (1) original research articles, (2) published in English, (3) utilizing isolated urolithin A (no mixtures or parent polyphenols) and (4) including at least one outcome relevant to sleep or sleep-related biological mechanisms, with no constraints on publication date. Our initial search produced 81 publications. After removing duplicates and screening publications according to inclusion criteria (for a flow diagram, see Supplementary Figure 1), five articles remained (Table 1). All were pre-clinical studies performed in mice or rats.
| First author (year) | Organism | Intervention | Dose | Control | Duration | Findings |
|---|---|---|---|---|---|---|
| Du (2024) (33) | Female C57BL/6J mice | Pre-treatment with UA prior to induction of inflammation | 20 mg/kg/day in oral gavage | 0.5% CMC and 0.1% TW80 daily | 1 week | Upregulation of clock-related genes (Bmal1, Per2, Clock, Cry1, Per3) in the SCN |
| Zhu (2024) (37) | 2-month-old male C57BL/6J mice | Pre-treatment with UA prior to 48-h SD; treatment continued during SD | 50 mg/kg/bw in oral gavage | Saline plus no SD, saline plus SD, and caffeine plus SD (10 mg/kg/bw) | 1 week | Pre-treatment with UA suppressed inflammation, microbial dysbiosis, and fatigue caused by SD |
| Zhou (2024) (35) | 6-month-old Sprague Dawley rats | Treatment with UA during a TSI condition to simulate microgravity | 20 mg/kg/day in oral gavage | PBS alone | 28 days | Treatment with UA mitigated dysfunctions in core body temperature, heart rate, and locomotor-activity rhythms caused by TSI |
| Misrani (2023) (38) | 3-month-old and 12-month-old C57BL/6J mice | Pre-treatment with UA prior to 48-h SD | 2.5 mg/kg or 10 mg/kg given i.p. | Saline plus no SD, saline plus SD, UA plus no SD | 1 week | Pre-treatment with UA suppressed neuroinflammation, mitochondrial dysfunction, and cognitive deficits caused by SD |
| Haraguchi (2022) (34) | MEFs and SCN explants from PER2::LUC mice | Treatment with UA after dexamethasone stimulation | 10–100 μM in MEFs, 5 or 50 μM in SCN explants | 0.1% DMSO | Acute (30 min) or up to 6 days | Treatment with UA delayed the rhythmic expression of Per2 in the SCN and prolonged the periodicity of Per2 expression in MEFs in a dose-dependent manner |
Summary of studies on the effect of urolithin A on pathways relevant to sleep health
CMC, carboxymethyl cellulose; i.p., intraperitonially; MEF, mouse embryonic fibroblasts; PBS, phosphate buffer saline; SCN, suprachiasmatic nucleus; SD, sleep deprivation; TSI, tail suspension and isolation; UA, urolithin A
Two studies (33, 34) reported effects of urolithin A on the central clock. Du et al. (33) analyzed the suprachiasmatic nucleus (SCN) of mice that underwent 1 week of urolithin A (20 mg/kg/day) or vehicle pre-treatment prior to dextran sulfate sodium-induced intestinal inflammation to study the effects of urolithin A on the expression of central clock genes. They reported a significant increase in the expression of Clock, Cry1, and Bmal1 genes. However, the significance of this effect is unclear as the authors did not include comparator groups without dextran sulfate sodium treatment, which would be needed meaningfully assess the effect of the treatment on circadian rhythmicity. Additionally, there was no assessment of protein levels downstream of changes in gene expression. Another experiment from Haraguchi et al. (34) used a mouse model that allows the visualization of Per2 expression rhythmicity via bioluminescence (PER2::LUC) to investigate the effect of varying doses of urolithin A on Per2 expression in mouse embryonic fibroblasts and cultured SCN explants. Among tested dose ranges of 10–100 μM, treatment with lower doses of urolithin A (10–20 μM) increased Per2 first and second peak amplitude, delayed first peak time, and prolonged period length in mouse embryonic fibroblasts. Similarly, in the SCN, a low dose of urolithin A treatment (5 vs. 50 μM) delayed the first peak time but had no effect on amplitude or period length. It is notable, however, that all urolithin A doses used in this study would exceed physiological thresholds for humans; peak plasma levels of urolithin A and its metabolites only reach about 110 ng/mL (equivalent to 1.2 μM) even after direct supplementation with 500 mg of urolithin A in healthy adults (28). Although these mouse models provide evidence that urolithin A can modulate the molecular machinery driving circadian rhythms, they have not evaluated the potential downstream favorable effects on sleep. Furthermore, additional experiments under forced desynchrony conditions are necessary to assess whether urolithin A can restore rhythmicity in adverse conditions.
Zhou et al. (35) investigated whether urolithin A can mitigate circadian rhythm disruption caused by simulated microgravity and isolation associated with spaceflight. They utilized a 30-degree tail suspension and isolation (TSI) model that kept the animals’ hindlimbs off the ground for 28 days to simulate microgravity. They reported that animals in the TSI group had lower circadian amplitude of core body temperature, heart rate, and locomotor-activity rhythms relative to control animals. They also reported that the SCN of rats in the TSI group had increased and decreased Rev-Erbα and Bmal1 protein levels, respectively, in addition to neuronal mitochondrial dysfunction, compared with that of rats in the control group. Rev-Erbα plays an important role in the regulation of the circadian oscillator, targeting Bmal1 and Clock directly to downregulate their transcription (36). When treated with urolithin A during TSI conditions, the circadian amplitude of core body temperature, heart rate, and locomotor-activity were restored to control conditions, and Rev-Erbα and Bmal1 protein levels in the SCN were decreased and increased, respectively.
The other two available studies (37, 38) evaluated whether urolithin A can counter adverse effects of acute sleep deprivation. Zhu et al. (37) tested the protective effects of urolithin A on sleep deprivation-induced fatigue and gut dysbiosis in male mice, including negative (regular sleep schedule, vehicle treatment) and positive (caffeine treatment) controls. Compared with negative controls, animals that received urolithin A treatment had preserved exercise capacity, measured as grip strength, and time to fatigue on a rota-rod test. Interestingly, these effects of urolithin A were comparable to those of caffeine (positive control), a well-known ergogenic aid (39). Sleep-deprived animals that received urolithin A vs. vehicle-treated controls also had a better inflammatory and oxidative stress profile, with significantly higher levels of glutathione peroxidase and lower levels of malondialdehyde in the liver as well as significantly lower circulating levels of C-reactive protein, interleukin-6, and tumor necrosis factor-α. With respect to the gut microbiota, treatment with urolithin A increased the abundance of commensal bacteria (Lactobacillus, Lachnospiraceae) and suppressed the proliferation of pathogenic bacteria (Clostridia, Candidatus) compared with vehicle-treated, sleep-deprived controls.
In a separate series of experiments of urolithin A treatment in the context of imposed sleep disturbance, Misrani et al. (38) investigated whether urolithin A could attenuate declines in cognition and brain health of animals. The authors reported that treatment with urolithin A preserved performance on a spatial learning and memory test (Morris water maze) after sleep deprivation relative to vehicle-treated sleep-deprived controls. They also reported that treatment with urolithin A prior to sleep deprivation blunted the overactivation of glial cells, attenuated the increase in pro-inflammatory cytokines (IL-6, TNF-α), and maintained mitochondrial dynamics and morphology integrity in the hippocampus, a brain region highly susceptible to sleep deprivation-induced deficits (40). The authors included two different urolithin A doses (2.5 and 10 mg/kg of body weight) but reported no evidence of a dose–response effect. There was also no beneficial effect of urolithin A treatment in the absence of sleep deprivation, and its effects on young and old mice were comparable.
The urolithin A doses used in the aforementioned mouse studies (37, 38) correspond to human-equivalent doses of approximately 14–284 mg/day (for a 70-kg human, based on body surface area allometric scaling). These doses are realistic to humans as isolated urolithin A has been shown to be safe and well-tolerated in middle-aged and older adults in doses up to 2,000 mg/day (21). Although these studies did not investigate the effects of urolithin A on sleep directly, they have shown that urolithin A may help mitigate the adverse effects of sleep deprivation, with potential to improve daytime function and perceived well-being in individuals with poor sleep health. However, major limitations remain: (1) only preclinical studies conducted in cell culture or animal models were identified for this review, and (2) the identified studies were not explicitly designed to measured changes in sleep. Thus, preclinical and clinical studies designed to evaluate sleep health are critically needed to address these gaps and elucidate the role of urolithin A in promoting good sleep health.
4 Urolithin A and sleep: potential mechanisms
Currently, we have identified no studies directly investigating the effect of urolithin A on sleep measures such as duration, efficiency, continuity, or timing. However, we identified emerging evidence on the effect of urolithin A on sleep-relevant pathways, which may provide plausibility and mechanistic support for future studies designed to study sleep directly. In this context, urolithin A may affect sleep through indirect and direct mechanisms.
4.1 Indirect evidence
One of the most promising indirect mechanisms is through the gut microbiota (41), which has been implicated in sleep regulation via the gut–brain axis (42, 43). Experimental studies in humans have shown that sleep disturbances such as circadian rhythm misalignment (44) and sleep deprivation (45) lead to gut microbiota dysbiosis, with a decrease in microbial diversity, an increase in Firmicutes/Bacteroidetes ratio, and a decrease in short-chain fatty acid production. Similar dysbiosis was also reported in sleep disorders such as obstructive sleep apnea (46) and insomnia (47). Conversely, interventions targeting the gut microbiota, such as treatment with prebiotics, have shown positive results in sleep outcomes in animal models (48–51). Animal studies have reported that urolithin A can modulate gut microbiota composition and improve intestinal barrier function (52–55) in models of intestinal inflammation. In the context of sleep, Zhu et al. (37) reported that treatment with urolithin A can alleviate community and functional impairments in the gut microbiota and preserve intestinal barrier function in sleep-deprived mice. Interestingly, core clock genes can affect circadian rhythmicity and composition of the gut microbiota, with studies in Bmal1– (56) and Per1/2-deficient mice (57) reporting abolishment of diurnal microbial oscillations and a shift toward a more proinflammatory gut microbiota profile. Importantly, disruption of sleep–wake cycles using a jetlag model recapitulated the effect of Per1/2 deletion on gut microbiota rhythmicity and homeostasis (57), highlighting the bidirectional relationship between sleep and gut microbiota and the mediating role of circadian mechanisms.
Urolithin A may also alleviate the inflammatory response induced by poor sleep. Sleep disruption increases neuroinflammation, especially in the hippocampus, with chronic sleep disruptions worsening inflammatory responses in the brain (40, 58, 59). Indeed, Misrani et al. (38) reported microglia and astrocytes overactivation, increase in proinflammatory cytokines, mitochondrial dysfunction, and abnormal neuronal morphology in the hippocampus of young and old mice subjected to 24 h of sleep deprivation, whereas treatment with urolithin A protected against these adverse effects. Additional studies using murine models of neurodegenerative diseases and lipopolysaccharide-induced inflammation provide further support for the protective neuroinflammatory effect of urolithin A (60–65). Interestingly, studies that included a mechanistic investigation have implicated Sirtuin 1 (SIRT1) as a mediator of urolithin A’s effect (62, 64, 65). Although there is no evidence of direct SIRT1 agonism, urolithin A is a well described mitophagy activator (63, 66, 67), contributing to improved mitochondrial efficiency and redox balance, which can indirectly improve SIRT1 expression and activity (68). Importantly, SIRT1 is directly involved in central clock regulation via modulation of transcriptional activity and stability of Per2 and PGC1α-mediated Bmal1 expression (69), and SIRT1 signaling disruption has been associated with sleep–wake cycle changes in aging (70, 71). Thus, urolithin A may help preserve circadian rhythm robustness and sleep–wake cycle regulation via indirect SIRT1 activation under conditions of exacerbated oxidative stress and inflammation.
4.2 Direct evidence
Regarding direct mechanisms, urolithin A may have potential modulatory effects on central clock genes (Clock, Bmal1, Per, Cry), a pathway partially supported by existing preclinical data. Although the studies testing the effect of urolithin A on the circadian clock included in this review (33–35) did not include sleep-related outcomes, central clock gene oscillations in the SCN govern sleep–wake cycles and are, therefore, mechanistically relevant to sleep. These studies (33–35) provide preliminary evidence that urolithin A can affect central clock components in the brain, potentially strengthening SCN output to regulate sleep architecture and stability, circadian timing, and sleep–wake cycling. Further, in vitro evidence (72) shows that urolithin A and its phase-II metabolites can cross the blood–brain barrier, an ability that would be necessary for their direct effects in the brain. Nonetheless, while circadian clock modulation can have effects on sleep timing and structure, the effects of this modulation on sleep require direct measures, such as electroencephalogram, actigraphy, and/or polysomnography.
4.3 Hypothesis-only evidence
Urolithin A may also have a modulatory effect on metabolites involved in sleep promotion and regulation. For example, urolithin A can increase the expression of tryptophan hydroxylase-2 (TPH2) in differentiated rat serotonergic raphe cells via an increase in the transcriptional activity of 1,25-dihydroxyvitamin D3 (73), the active form of vitamin D. TPH2 is involved in the metabolism of tryptophan to serotonin; indeed, an increase in TPH2 expression was accompanied by a 3- to 4-fold increase in serotonin concentration in culture medium (73). As serotonin has been shown to have critical functions in sleep (74), with disruption of the serotonergic system leading to short sleep duration and altered homeostatic sleep drive (75), urolithin A may improve sleep by stimulating the serotonergic system. As a caveat, the urolithin A doses (10–20 μM, equivalent to about 2.3–4.6 μg/mL) utilized in the study were much higher than levels achieved in human circulation (<1 μM or <0.5 μg/mL). Nonetheless, this potential mechanism merits further investigation in the context of sleep disorders such as insomnia. Figure 1 summarizes the proposed theoretical framework for the effect of urolithin A on pathways relevant to sleep health.
5 Future directions and conclusion
Although studies directly investigating the effects of urolithin A on sleep are lacking, there is mechanistic plausibility supporting this potential relationship, representing a novel direction in polyphenol-derived microbial metabolite research. Given the high prevalence of sleep disturbances and sleep disorders in the US population and the considerable side effects of sleep medications, non-pharmacological alternatives to improve sleep health are critically needed.
Several outstanding questions and methodological considerations remain for future studies seeking to investigate the effect of urolithin A on sleep. For cell-based studies, it is imperative that they utilize plausible doses of urolithin A (<1 μM or <0.5 μg/mL) and its main phase II metabolite, urolithin A-glucuronide to ensure that findings can translate to human physiology. Regarding preclinical studies, there are several unexplored research opportunities for experimental animal studies using, for example, (1) chronic short sleep duration or chronic sleep fragmentation models, (2) circadian misalignment/jetlag models including a urolithin A intervention arm, and (3) germ-free mice or fecal matter transplant to investigate whether the effects of urolithin A are dependent on the microbiota. The inclusion of proper controls (negative and positive controls) as well as preventive/protective versus treatment (i.e., treatment with urolithin A before versus after exposure) of sleep disturbances and disorders designs should be considered to evaluate potential benefits of urolithin A in the prevention and management of sleep conditions and their downstream adverse health effects.
Regarding clinical studies, well-designed clinical trials are needed to investigate the effect of urolithin A on sleep in humans. These trials should utilize a combination of objective and self-reported measures of sleep, such as actigraphy and sleep-related questionnaires, to capture the multidimensionality of sleep health. Including circadian rhythm markers such as dim light melatonin onset would strengthen the informative value of these trials, where feasible. Urolithin A has been shown to be safe and well tolerated in adults (21, 76), offering a unique opportunity to utilize an isolated polyphenol-derived microbial metabolite in supraphysiological doses that could not be achieved by dietary means alone. Finally, studies using isolated urolithin A or its parent polyphenols should consider individuals’ metabotypes as systemic factors associated with each metabotype may affect intervention responsiveness, such as stratifying participants by metabotype at baseline.
Statements
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by grants from the National Institutes of Health (R01AG075834, R21AG080775 awarded to AY; R35HL155670 and R01HL142648 awarded to M-PS-O; R01HL173190 awarded to FZ) and from the American Heart Association (24DIVSUP1282484 awarded to AP-L)
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Generative AI statement
The author(s) declared that Generative AI was not used in the creation of this manuscript
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher
Supplementary material
The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2026.1779855/full#supplementary-material
SUPPLEMENTARY FIGURE 1
Flow diagram of studies identified in our literature search (PubMed, Scopus, and Ovis) and included in this mini-review
References
St-OngeMPAggarwalBFernandez-MendozaJJohnsonDKlineCEKnutsonKLet al. Multidimensional sleep health: definitions and implications for cardiometabolic health: a scientific statement from the American Heart Association. Circ Cardiovasc Qual Outcomes. (2025) 18:e000139. doi: 10.1161/HCQ.0000000000000139
2.
BuysseDJ. Sleep health: can we define it? Does it matter?Sleep. (2014) 37:9–17. doi: 10.5665/sleep.3298
3.
ShanZMaHXieMYanPGuoYBaoWet al. Sleep duration and risk of type 2 diabetes: a meta-analysis of prospective studies. Diabetes Care. (2015) 38:529–37. doi: 10.2337/dc14-2073
4.
LiuHZhuHLuQYeWHuangTLiYet al. Sleep features and the risk of type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Med. (2025) 57:2447422. doi: 10.1080/07853890.2024.2447422
5.
CappuccioFPCooperDD’EliaLStrazzulloPMillerMA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. (2011) 32:1484–92. doi: 10.1093/eurheartj/ehr007
6.
HosseiniKSoleimaniHTavakoliKMaghsoudiMHeydariNFarahvashYet al. Association between sleep duration and hypertension incidence: systematic review and meta-analysis of cohort studies. PLoS One. (2024) 19:e0307120. doi: 10.1371/journal.pone.0307120
7.
ShiLChenSJMaMYBaoYPHanYWangYMet al. Sleep disturbances increase the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev. (2018) 40:4–16. doi: 10.1016/j.smrv.2017.06.010
8.
XuWTanCCZouJJCaoXPTanL. Sleep problems and risk of all-cause cognitive decline or dementia: an updated systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. (2020) 91:236–44. doi: 10.1136/jnnp-2019-321896
9.
BubuOMBrannickMMortimerJUmasabor-BubuOSebastiaoYVWenYet al. Sleep, cognitive impairment, and Alzheimer’s disease: a systematic review and meta-analysis. Sleep. (2017) 40:zsw032. doi: 10.1093/sleep/zsw032
10.
ItaniOJikeMWatanabeNKaneitaY. Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Med. (2017) 32:246–56. doi: 10.1016/j.sleep.2016.08.006
11.
DiHGuoYDaghlasIWangLLiuGPanAet al. Evaluation of sleep habits and disturbances among US adults, 2017–2020. JAMA Netw Open. (2022) 5:e2240788. doi: 10.1001/jamanetworkopen.2022.40788
12.
MartinSSAdayAWAlmarzooqZIAndersonCAMAroraPAveryCLet al. 2024 heart disease and stroke statistics: a report of us and global data from the American Heart Association. Circulation. (2024) 149:e347–913. doi: 10.1161/CIR.0000000000001209
13.
ZuraikatFMWoodRABarraganRSt-OngeMP. Sleep and diet: mounting evidence of a cyclical relationship. Annu Rev Nutr. (2021) 41:309–32. doi: 10.1146/annurev-nutr-120420-021719
14.
GodosJFerriRLanzaGCaraciFVistorteAORYelamos TorresVet al. Mediterranean diet and sleep features: a systematic review of current evidence. Nutrients. (2024) 16:282. doi: 10.3390/nu16020282
15.
WilsonKSt-OngeMPTasaliE. Diet composition and objectively assessed sleep quality: a narrative review. J Acad Nutr Diet. (2022) 122:1182–95. doi: 10.1016/j.jand.2022.01.007
16.
QuideauSDeffieuxDDouat-CasassusCPouyseguL. Plant polyphenols: chemical properties, biological activities, and synthesis. Angew Chem Int Ed Engl. (2011) 50:586–621. doi: 10.1002/anie.201000044
17.
Perez-JimenezJAgnantKLamuela-RaventosRMSt-OngeMP. Dietary polyphenols and sleep modulation: current evidence and perspectives. Sleep Med Rev. (2023) 72:101844. doi: 10.1016/j.smrv.2023.101844
18.
HibiM. Potential of polyphenols for improving sleep: a preliminary results from review of human clinical trials and mechanistic insights. Nutrients. (2023) 15:1257. doi: 10.3390/nu15051257
19.
WangWLiuTDingYZhangY. Effects of polyphenol-rich interventions on sleep disorders: a systematic review and meta-analysis. Curr Res Food Sci. (2023) 6:100462. doi: 10.1016/j.crfs.2023.100462
20.
Cortes-MartinASelmaMVTomas-BarberanFAGonzalez-SarriasAEspinJC. Where to look into the puzzle of polyphenols and health? The postbiotics and gut microbiota associated with human metabotypes. Mol Nutr Food Res. (2020) 64:e1900952. doi: 10.1002/mnfr.201900952
21.
AndreuxPABlanco-BoseWRyuDBurdetFIbbersonMAebischerPet al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab. (2019) 1:595–603. doi: 10.1038/s42255-019-0073-4
22.
LiuSD’AmicoDShanklandEBhayanaSGarciaJMAebischerPet al. Effect of urolithin A supplementation on muscle endurance and mitochondrial health in older adults: a randomized clinical trial. JAMA Netw Open. (2022) 5:e2144279. doi: 10.1001/jamanetworkopen.2021.44279
23.
ZhaoHZhuHYunHLiuJSongGTengJet al. Assessment of urolithin A effects on muscle endurance, strength, inflammation, oxidative stress, and protein metabolism in male athletes with resistance training: an 8-week randomized, double-blind, placebo-controlled study. J Int Soc Sports Nutr. (2024) 21:2419388. doi: 10.1080/15502783.2024.2419388
24.
SinghAD’AmicoDAndreuxPAFouassierAMBlanco-BoseWEvansMet al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell Rep Med. (2022) 3:100633. doi: 10.1016/j.xcrm.2022.100633
25.
Garcia-VillalbaRGimenez-BastidaJACortes-MartinAAvila-GalvezMATomas-BarberanFASelmaMVet al. Urolithins: a comprehensive update on their metabolism, bioactivity, and associated gut microbiota. Mol Nutr Food Res. (2022) 66:e2101019. doi: 10.1002/mnfr.202101019
26.
SelmaMVBeltranDGarcia-VillalbaREspinJCTomas-BarberanFA. Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct. (2014) 5:1779–84. doi: 10.1039/c4fo00092g
27.
Tomas-BarberanFAGonzalez-SarriasAGarcia-VillalbaRNunez-SanchezMASelmaMVGarcia-ConesaMTet al. Urolithins, the rescue of “old” metabolites to understand a “new” concept: metabotypes as a nexus among phenolic metabolism, microbiota dysbiosis, and host health status. Mol Nutr Food Res. (2017) 61:1500901. doi: 10.1002/mnfr.201500901
28.
SinghAD’AmicoDAndreuxPADunngalvinGKernTBlanco-BoseWet al. Direct supplementation with urolithin A overcomes limitations of dietary exposure and gut microbiome variability in healthy adults to achieve consistent levels across the population. Eur J Clin Nutr. (2022) 76:297–308. doi: 10.1038/s41430-021-00950-1
29.
ZhangXSandhuAEdirisingheIBurton-FreemanBM. Plasma and urinary (poly)phenolic profiles after 4-week red raspberry (Rubus idaeus L.) intake with or without fructo-oligosaccharide supplementation. Molecules. (2020) 25:4777. doi: 10.3390/molecules25204777
30.
González-SarríasAGarcía-VillalbaRRomo-VaqueroMAlasalvarCÖremAZafrillaPet al. Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: a randomized clinical trial. Mol Nutr Food Res. (2017) 61:1600830. doi: 10.1002/mnfr.201600830
31.
Cortes-MartinAGarcia-VillalbaRGonzalez-SarriasARomo-VaqueroMLoria-KohenVRamirez-de-MolinaAet al. The gut microbiota urolithin metabotypes revisited: the human metabolism of ellagic acid is mainly determined by aging. Food Funct. (2018) 9:4100–6. doi: 10.1039/c8fo00956b
32.
Romo-VaqueroMCortes-MartinALoria-KohenVRamirez-de-MolinaAGarcia-MantranaIColladoMCet al. Deciphering the human gut microbiome of urolithin metabotypes: association with enterotypes and potential cardiometabolic health implications. Mol Nutr Food Res. (2019) 63:e1800958. doi: 10.1002/mnfr.201800958
33.
DuYChenXKajiwaraSOriharaK. Effect of urolithin A on the improvement of circadian rhythm dysregulation in intestinal barrier induced by inflammation. Nutrients. (2024) 16:2263. doi: 10.3390/nu16142263
34.
HaraguchiADuYShiraishiRTakahashiYNakamuraTJShibataS. Oak extracts modulate circadian rhythms of clock gene expression in vitro and wheel-running activity in mice. Sleep Biol Rhythms. (2022) 20:255–66. doi: 10.1007/s41105-021-00365-2
35.
ZhouSLiXLiangFJiGLvKYuanYet al. Mitophagy regulates the circadian rhythms by degrading NR1D1 in simulated microgravity and isolation environments. Int J Mol Sci. (2024) 25:4853. doi: 10.3390/ijms25094853
36.
CrumbleyCBurrisTP. Direct regulation of CLOCK expression by REV-ERB. PLoS One. (2011) 6:e17290. doi: 10.1371/journal.pone.0017290
37.
ZhuHZhaoHQianHLiuC. Urolithin A ameliorates athletic ability and intestinal microbiota in sleep deprivation from the perspective of the gut-muscle axis. Mol Nutr Food Res. (2024) 68:e2300599. doi: 10.1002/mnfr.202300599
38.
MisraniATabassumSZhangZYTanSHLongC. Urolithin A prevents sleep-deprivation-induced neuroinflammation and mitochondrial dysfunction in young and aged mice. Mol Neurobiol. (2024) 61:1448–66. doi: 10.1007/s12035-023-03651-x
39.
GuestNSVanDusseldorpTANelsonMTGrgicJSchoenfeldBJJenkinsNDMet al. International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. (2021) 18:1. doi: 10.1186/s12970-020-00383-4
40.
HavekesRAbelT. The tired hippocampus: the molecular impact of sleep deprivation on hippocampal function. Curr Opin Neurobiol. (2017) 44:13–9. doi: 10.1016/j.conb.2017.02.005
41.
St-OngeMPZuraikatFM. Reciprocal roles of sleep and diet in cardiovascular health: a review of recent evidence and a potential mechanism. Curr Atheroscler Rep. (2019) 21:11. doi: 10.1007/s11883-019-0772-z
42.
WangZWangZLuTChenWYanWYuanKet al. The microbiota-gut-brain axis in sleep disorders. Sleep Med Rev. (2022) 65:101691. doi: 10.1016/j.smrv.2022.101691
43.
SenPMolinero-PerezAO’RiordanKJMcCaffertyCPO’HalloranKDCryanJF. Microbiota and sleep: awakening the gut feeling. Trends Mol Med. (2021) 27:935–45. doi: 10.1016/j.molmed.2021.07.004
44.
LiuZWeiZYChenJChenKMaoXLiuQet al. Acute sleep-wake cycle shift results in community alteration of human gut microbiome. mSphere. (2020) 5:e00914-19. doi: 10.1128/mSphere.00914-19
45.
WangZChenWHLiSXHeZMZhuWLJiYBet al. Gut microbiota modulates the inflammatory response and cognitive impairment induced by sleep deprivation. Mol Psychiatry. (2021) 26:6277–92. doi: 10.1038/s41380-021-01113-1
46.
KoCYLiuQQSuHZZhangHPFanJMYangJHet al. Gut microbiota in obstructive sleep apnea-hypopnea syndrome: disease-related dysbiosis and metabolic comorbidities. Clin Sci. (2019) 133:905–17. doi: 10.1042/CS20180891
47.
LiuBLinWChenSXiangTYangYYinYet al. Gut microbiota as an objective measurement for auxiliary diagnosis of insomnia disorder. Front Microbiol. (2019) 10:1770. doi: 10.3389/fmicb.2019.01770
48.
ZhangYChengLLiuYZhangRWuZChengKet al. Omics analyses of intestinal microbiota and hypothalamus clock genes in circadian disturbance model mice fed with green tea polyphenols. J Agric Food Chem. (2022) 70:1890–901. doi: 10.1021/acs.jafc.1c07594
49.
BowersSJSummaKCThompsonRSGonzalezAVargasFOlkerCet al. A prebiotic diet alters the fecal microbiome and improves sleep in response to sleep disruption in rats. Front Neurosci. (2022) 16:889211. doi: 10.3389/fnins.2022.889211
50.
ThompsonRSGaffneyMHopkinsSKelleyTGonzalezABowersSJet al. Ruminiclostridium 5, Parabacteroides distasonis, and bile acid profile are modulated by prebiotic diet and associate with facilitated sleep/clock realignment after chronic disruption of rhythms. Brain Behav Immun. (2021) 97:150–66. doi: 10.1016/j.bbi.2021.07.006
51.
ThompsonRSVargasFDorresteinPCChichlowskiMBergBMFleshnerM. Dietary prebiotics alter novel microbial dependent fecal metabolites that improve sleep. Sci Rep. (2020) 10:3848. doi: 10.1038/s41598-020-60679-y
52.
AbdulrahmanAOAlzubaidiMYNadeemMSKhanJARatherIAKhanMI. Effects of urolithins on obesity-associated gut dysbiosis in rats fed on a high-fat diet. Int J Food Sci Nutr. (2021) 72:923–34. doi: 10.1080/09637486.2021.1886255
53.
SinghRChandrashekharappaSBodduluriSRBabyBVHegdeBKotlaNGet al. Enhancement of the gut barrier integrity by a microbial metabolite through the Nrf2 pathway. Nat Commun. (2019) 10:89. doi: 10.1038/s41467-018-07859-7
54.
LarrosaMGonzalez-SarriasAYanez-GasconMJSelmaMVAzorin-OrtunoMTotiSet al. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-a in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem. (2010) 21:717–25. doi: 10.1016/j.jnutbio.2009.04.012
55.
MaMWangYFanSHuangYSuXLuC. Urolithin A alleodulating microbial tryptophan metabolism, and triggering AhR activation. J Agric Food Chem. (2023) 71:7710–22. doi: 10.1021/acs.jafc.3c00830
56.
LiangXBushmanFDFitzGeraldGA. Rhythmicity of the intestinal microbiota is regulated by gender and the host circadian clock. Proc Natl Acad Sci USA. (2015) 112:10479–84. doi: 10.1073/pnas.1501305112
57.
ThaissCAZeeviDLevyMZilberman-SchapiraGSuezJTengelerACet al. Transkingdom control of microbiota diurnal oscillations promotes metabolic homeostasis. Cell. (2014) 159:514–29. doi: 10.1016/j.cell.2014.09.048
58.
OwenJEVeaseySC. Impact of sleep disturbances on neurodegeneration: insight from studies in animal models. Neurobiol Dis. (2020) 139:104820. doi: 10.1016/j.nbd.2020.104820
59.
ZhuBDongYXuZGompfHSWardSAXueZet al. Sleep disturbance induces neuroinflammation and impairment of learning and memory. Neurobiol Dis. (2012) 48:348–55. doi: 10.1016/j.nbd.2012.06.022
60.
XuNDuCYuYLiYGaoSYuSet al. Urolithin A improves Parkinson’s disease-associated cognitive impairment through modulation of neuroinflammation and neuroplasticity. Exp Neurol. (2025) 393:115395. doi: 10.1016/j.expneurol.2025.115395
61.
GongZHuangJXuBOuZZhangLLinXet al. Urolithin A attenuates memory impairment and neuroinflammation in APP/PS1 mice. J Neuroinflammation. (2019) 16:62. doi: 10.1186/s12974-019-1450-3
62.
HouYChuXParkJHZhuQHussainMLiZet al. Urolithin A improves Alzheimer’s disease cognition and restores mitophagy and lysosomal functions. Alzheimers Dement. (2024) 20:4212–33. doi: 10.1002/alz.13847
63.
QiuJChenYZhuoJZhangLLiuJWangBet al. Urolithin A promotes mitophagy and suppresses NLRP3 inflammasome activation in lipopolysaccharide-induced BV2 microglial cells and MPTP-induced Parkinson’s disease model. Neuropharmacology. (2022) 207:108963. doi: 10.1016/j.neuropharm.2022.108963
64.
VelagapudiRLepiarzIEl-BakoushAKatolaFOBhatiaHFiebichBLet al. Induction of autophagy and activation of SIRT-1 deacetylation mechanisms mediate neuroprotection by the pomegranate metabolite urolithin A in BV2 microglia and differentiated 3D human neural progenitor cells. Mol Nutr Food Res. (2019) 63:e1801237. doi: 10.1002/mnfr.201801237
65.
WuYYuanQMaYZhouXWangGWangSet al. Dietary intervention with the gut microbial metabolite urolithin A attenuates lipopolysaccharide-induced neuroinflammation and cognitive deficits (2023) 67:e2200401. doi: 10.1002/mnfr.202200401
66.
LuanPD’AmicoDAndreuxPALaurilaPPWohlwendMLiHet al. Urolithin A improves muscle function by inducing mitophagy in muscular dystrophy. Sci Transl Med. (2021) 13:eabb0319. doi: 10.1126/scitranslmed.abb0319
67.
RyuDMouchiroudLAndreuxPAKatsyubaEMoullanNNicolet-Dit-FelixAAet al. Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents. Nat Med. (2016) 22:879–88. doi: 10.1038/nm.4132
68.
SalminenAKaarnirantaKKauppinenA. Crosstalk between oxidative stress and Sirt1: impact on the aging process. Int J Mol Sci. (2013) 14:3834–59. doi: 10.3390/ijms14023834
69.
FoteinouPTVenkataramanAFranceyLJAnafiRCHogeneschJBDoyleFJ3rd.Computational and experimental insights into the circadian effects of Sirt1. Proc Natl Acad Sci USA. (2018) 115:11643–8. doi: 10.1073/pnas.1803410115
70.
SatohABraceCSRensingNCliftenPWozniakDFHerzogEDet al. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. (2013) 18:416–30. doi: 10.1016/j.cmet.2013.07.013
71.
PanossianLFenikPZhuYZhanGMcBurneyMWVeaseyS. Sirt1 regulation of wakefulness and senescence-like phenotype in wake neurons. J Neurosci. (2011) 31:4025–36. doi: 10.1523/JNEUROSCI.5166-10.2011
72.
Garay-MayolBGimenez-BastidaJALopez-CanovasDJPoveda-LoraSNavarro-OrcajadaSBritoMAet al. Urolithins and their phase II conjugates cross the blood-brain barrier and exert a stimulus-dependent anti-inflammatory effect on microglial cells by inhibiting NF-κB nuclear translocation. Food Funct. (2025) 16:9006–21. doi: 10.1039/D5FO03678J
73.
LivingstonSMallickSLucasDASabirMSSabirZLPurdinHet al. Pomegranate derivative urolithin A enhances vitamin D receptor signaling to amplify serotonin-related gene induction by 1,25-dihydroxyvitamin D. Biochem Biophys Rep. (2020) 24:100825. doi: 10.1016/j.bbrep.2020.100825
74.
CespuglioR. Serotonin: its place today in sleep preparation, triggering or maintenance. Sleep Med. (2018) 49:31–9. doi: 10.1016/j.sleep.2018.05.034
75.
OikonomouGAltermattMZhangRWCoughlinGMMontzCGradinaruVet al. The serotonergic raphe promote sleep in zebrafish and mice. Neuron. (2019) 103:686–701.e8. doi: 10.1016/j.neuron.2019.05.038
76.
HeilmanJAndreuxPTranNRinschCBlanco-BoseW. Safety assessment of urolithin A, a metabolite produced by the human gut microbiota upon dietary intake of plant derived ellagitannins and ellagic acid. Food Chem Toxicol. (2017) 108:289–97. doi: 10.1016/j.fct.2017.07.050
Summary
Keywords
gut microbiota, polyphenol-derived microbial metabolites, polyphenols, sleep, urolithin A
Citation
Pinaffi-Langley ACC, Zuraikat FM, St-Onge M-P and Yabluchanskiy A (2026) Potential impact of urolithin A on pathways relevant to sleep health: a mini review. Front. Nutr. 13:1779855. doi: 10.3389/fnut.2026.1779855
Received
02 January 2026
Revised
02 February 2026
Accepted
19 February 2026
Published
04 March 2026
Volume
13 – 2026
Edited by
Karolina Wojtunik-Kulesza, Medical University of Lublin, Poland
Reviewed by
Changhao He, Zhejiang Chinese Medical University, China
Adriano Dos Santos, University of Bern, Switzerland
Updates
Copyright
© 2026 Pinaffi-Langley, Zuraikat, St-Onge and Yabluchanskiy
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher
